[Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
OBJECTIVE
To establish 18 fluorocholine-positron emission tomography/computed tomography (F-PET/CT) performances for the detection of local recurrence in a population of patients with biochemical failure after primary curative treatment for localized prostate carcinoma.


METHODS
From February 2011 to February 2014, 55 patients underwent a F-PET/CT for biochemical relapse after primary radical therapy for prostate cancer localized or locally advanced. Primary therapies for prostate cancer were 19 radical prostatectomy, 18 radiotherapy, 13 radiotherapy with hormonal treatment, 3 brachytherapy. The median age was 65 years (50-79). The initial staging was 17 T1, 23 T2 and 15 T3, 52 were N0 and N1 3. The median PSA was 12 (3-127). The Gleason score was less than 7, equal to 7 and greater than 7 at 21, 25 and 9 patients respectively. The average time to recurrence was 69.5 months (8-147) with a median PSA of 2.9 ng/mL (0.48-41).


RESULTS
In 42 cases, F-PET/CT showed uptake, suggesting a recurrence, metastatic (6), nodal (26) or local isolated (10). The focal uptake in PET commissioned in 5 cases prostate biopsy, confirming the histological recurrence of prostate cancer in 4 cases. Among the 10 patients with isolated local recurrence, 8 underwent salvage radiotherapy. Of the 13 cases where the (F-PET/CT) showed no recurrence, 7 multiparametric MRI were performed. The MRI showed a local recurrence in 3 patients, the diagnoses were confirmed with prostate biopsy for two of them.


CONCLUSIONS
In our study, for the patients with biochemical relapse of prostate adenocarcinoma localized or locally advanced, (F-PET/CT) was able to detect local recurrence isolated in nearly half the cases but did not show sufficient sensitivity to exclude recurrence local if negative. It does not replace MRI or additional prostate biopsy.
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France. Electronic address: dponcet.smu@gmail.com.
D
D
Poncet
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
V
V
Arnoux
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
J-L
JL
Descotes
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
J-J
JJ
Rambeaud
Service de radiothérapie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
C
C
Verry
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
N
N
Terrier
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
B
B
Boillot
Service de médecine nucléaire, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
J
J
Dubreuil
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
C
C
Lanchon
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
D
D
Carnicelli
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
G
G
Fiard
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.
J-A
JA
Long
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000628:therapy; D000368:Aged; D002794:Choline / Q000031:analogs & derivatives*; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
D005462:Fluorine Radioisotopes; C514960:fluorocholine; D002794:Choline
Biochemical relapse; Cancer de prostate; Choline; Positron emission tomography (PET); Prostate cancer; Recurrence; Récidive biochimique; Tomographie à émission de positons